Calsequestrin 2 and arrhythmias

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 6, 2012, Pages

  Faggioni, Michela ^a   Knollmann, Björn C ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium handling; Cardiac arrhythmia; Catecholaminergic polymorphic ventricular tachycardia

Indexed keywords

ANTHRACYCLINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALSEQUESTRIN; CALSEQUESTRIN 2; NEUROLEPTIC AGENT; PROPAFENONE; RYANODINE RECEPTOR 2; UNCLASSIFIED DRUG; VERAPAMIL;

ARRHYTHMOGENESIS; BECKER MUSCULAR DYSTROPHY; CALCIUM TRANSPORT; CARDIOTOXICITY; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CELL FUNCTION; CELLULAR DISTRIBUTION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BINDING; DRUG EFFICACY; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE ARRHYTHMIA; HEREDITY; HUMAN; MISSENSE MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SARCOPLASMIC RETICULUM; SINGLE NUCLEOTIDE POLYMORPHISM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM SIGNALING; CALSEQUESTRIN; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HEART CONDUCTION SYSTEM; HUMANS; MICE; PHENOTYPE; SARCOPLASMIC RETICULUM; TACHYCARDIA, VENTRICULAR;

EID: 84858163332     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00779.2011     Document Type: Review

References (110)

1. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm 8: 1308-1339, 2011.
2. Arai M, Tomaru K, Takizawa T, Sekiguchi K, Yokoyama T, Suzuki T, Nagai R. Sarcoplasmic reticulum genes are selectively downregulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 30: 243-254, 1998.
3. Baher AA, Uy M, Xie F, Garfinkel A, Qu Z, Weiss JN. Bidirectional ventricular tachycardia: ping pong in the His-Purkinje system. Heart Rhythm 8: 599-605, 2010.
4. Bal NC, Jena N, Sopariwala D, Balaraju T, Shaikh S, Bal C, Sharon A, Gyorke S, Periasamy M. Probing cationic selectivity of cardiac calsequestrin and its CPVT mutants. Biochem J 435: 391-399, 2011.
5. Bal NC, Sharon A, Gupta SC, Jena N, Shaikh S, Gyorke S, Periasamy M. The catecholaminergic polymorphic ventricular tachycardia mutation R33Q disrupts the N-terminal structural motif that regulates reversible calsequestrin polymerization. J Biol Chem 285: 17188-17196, 2010.
6. Belevych AE, Terentyev D, Terentyeva R, Nishijima Y, Sridhar A, Hamlin RL, Carnes CA, Gyorke S. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. Cardiovasc Res 90: 493-502, 2011.
7. Bers DM. Cardiac excitation-contraction coupling. Nature 415: 198-205, 2002.
8. Bers DM. Macromolecular complexes regulating cardiac ryanodine receptor function. J Mol Cell Cardiol 37: 417-429, 2004.
9. 2+ transport. Circ Res 93: 487-490, 2003.
10. Berte B, Eyskens B, Meyfroidt G, Willems R. Bidirectional ventricular tachycardia in fulminant myocarditis. Europace 10: 767-768, 2008.
11. Campbell KP, MacLennan DH, Jorgensen AO, Mintzer MC. Purification and characterization of calsequestrin from canine cardiac sarcoplasmic reticulum and identification of the 53,000 dalton glycoprotein. J Biol Chem 258: 1197-1204, 1983.
12. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O, Anumonwo J, Pandit SV, Vikstrom K, Napolitano C, Priori SG, Jalife J. Arrhythmogenic mechanisms in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 101: 1039-1048, 2007.
13. Charlier HA Jr, Olson RD, Thornock CM, Mercer WK, Olson DR, Broyles TS, Muhlestein DJ, Larson CL, Cusack BJ, and Shadle SE. Investigations of calsequestrin as a target for anthracyclines: comparison of functional effects of daunorubicin, daunorubicinol, and trifluoperazine. Mol Pharmacol 67: 1505-1512, 2005.
14. 2+ and trigger ventricular arrhythmias in mice. Circ Res 101: 617-626, 2007.
15. Chopra N, Knollmann BC. Cardiac calsequestrin: the new kid on the block in arrhythmias. J Cardiovasc Electrophysiol 20: 1179-1185, 2009.
16. Chopra N, Laver D, Davies SS, Knollmann BC. Amitriptyline activates cardiac ryanodine channels and causes spontaneous sarcoplasmic reticulum calcium release. Mol Pharmacol 75: 183-195, 2009.
17. 2 release units, impaired excitationcontraction coupling, and cardiac arrhythmias. Proc Natl Acad Sci USA 106: 7636-7641, 2009.
18. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM, Wilkinson JD, Orav EJ, Cuniberti L, Salbert BA, Lipshultz SE. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 155: 998-1005, 2008.
19. Cozens B, Reithmeier RA. Size and shape of rabbit skeletal muscle calsequestrin. J Biol Chem 259: 6248-6252, 1984.
20. de la Fuente S, Van Langen IM, Postma AV, Bikker H, Meijer A. A case of catecholaminergic polymorphic ventricular tachycardia caused by two calsequestrin 2 mutations. Pacing Clin Electrophysiol 31: 916-919, 2008.
21. di Barletta MR, Viatchenko-Karpinski S, Nori A, Memmi M, Terentyev D, Turcato F, Valle G, Rizzi N, Napolitano C, Gyorke S, Volpe P, Priori SG. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. Circulation 114: 1012-1019, 2006.
22. Di Maio A, Ter Keurs HE, Franzini-Armstrong C. T-tubule profiles in Purkinje fibres of mammalian myocardium. J Muscle Res Cell Motil 28: 115-121, 2007.
23. 2+ handling and causes complex ventricular arrhythmias in mice. Cardiovasc Res 75: 69-78, 2007.
24. Franzini-Armstrong C, Kenney LJ,. The structure of calsequestrin in triads of vertebrate skeletal muscle: a deep-etch study. J Cell Biol 105: 49-56, 1987.
25. Galimberti ES, Knollmann BC. Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca(2+) waves in permeabilized myocytes lacking calsequestrin. J Mol Cell Cardiol 51: 760-768, 2011.
26. 2+ handling, contractility, and heart failure. Am J Physiol Heart Circ Physiol 293: H728-H734, 2007.
27. Grimard C, De Labriolle A, Charbonnier B, Babuty D. Bidirectional ventricular tachycardia resulting from digoxin toxicity. J Cardiovasc Electrophysiol 16: 807-808, 2005.
28. Gyorke I, Hester N, Jones LR, Gyorke S. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. Biophys J 86: 2121-2128, 2004.
29. Han P, Cai W, Wang Y, Lam CK, Arvanitis DA, Singh V, Chen S, Zhang H, Zhang R, Cheng H, Kranias EG. Catecholaminergic induced arrhythmias in failing cardiomyocytes associated with human HRCS96A variant overexpression. Am J Physiol Heart Circ Physiol 301: H1588-H1595, 2011.
30. Hanna AD, Janczura M, Cho E, Dulhunty AF, Beard NA. Multiple actions of the anthracycline daunorubicin on cardiac ryanodine receptors. Mol Pharmacol 80: 538-549, 2011.
31. 2+ stores in cardiomyocytes. Cardiovasc Res 88: 75-82, 2010.
32. Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 119: 2426-2434, 2009.
33. 2+ release events generated by an interaction between ryanodine and IP3 receptors in canine Purkinje cells. J Mol Cell Cardiol 45: 176-184, 2008.
34. Houle TD, Ram ML, Cala SE. Calsequestrin mutant D307H exhibits depressed binding to its protein targets and a depressed response to calcium. Cardiovasc Res 64: 227-233, 2004.
35. 2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 4: 128-135, 2011.
36. Iyer V, Hajjar RJ, Armoundas AA. Mechanisms of abnormal calcium homeostasis in mutations responsible for catecholaminergic polymorphic ventricular tachycardia. Circ Res 100: e22-31, 2007.
37. Jones LR, Cala SE. Biochemical evidence for functional heterogeneity of cardiac sarcoplasmic reticulum vesicles. J Biol Chem 256: 11809-11818, 1981.
38. 2 signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J Clin Invest 101: 1385-1393, 1998.
39. Kalyanasundaram A, Bal NC, Franzini-Armstrong C, Knollmann BC, Periasamy M. The calsequestrin mutation CASQ2D307H does not affect protein stability and targeting to the junctional sarcoplasmic reticulum but compromises its dynamic regulation of calcium buffering. J Biol Chem 285: 3076-3083, 2010.
40. Kalyanasundaram A, Viatchenko-Karpinski S, Belevych A, Lacombe VA, Hwang HS, Knollmann BC, Gyorke S, Periasamy M. Functional consequences of stably expressing a mutant calsequestrin (Casq2d307h) in the Casq2 null background. Am J Physiol Heart Circ Physiol 302: H253-H261, 2012.
41. Kang C, Nissen MS, Sanchez EJ, Lam KS, Milting H. Potential adverse interaction of human cardiac calsequestrin. Eur J Pharmacol 646: 12-21, 2010.
42. Kang G, Giovannone SF, Liu N, Liu FY, Zhang J, Priori SG, Fishman GI. Purkinje cells from RyR2 mutant mice are highly arrhythmogenic but responsive to targeted therapy. Circ Res 107: 512-519, 2010.
43. Kashimura TBS, Trafford AW, Napolitano C, Priori SG, Eisner DA, Venetucci LA. In the RyR2(R4496C) mouse model of CPVT, β-adrenergic stimulation induces Ca waves by increasing SR Ca content and not by decreasing the threshold for Ca waves. Circ Res 107: 1483-1489, 2010.
44. Kiarash A, Kelly CE, Phinney BS, Valdivia HH, Abrams J, Cala SE. Defective glycosylation of calsequestrin in heart failure. Cardiovasc Res 63: 264-272, 2004.
45. Kim E, Youn B, Kemper L, Campbell C, Milting H, Varsanyi M, Kang C. Characterization of human cardiac calsequestrin and its deleterious mutants. J Mol Biol 373: 1047-1057, 2007.
46. Kirchhefer U, Wehrmeister D, Postma AV, Pohlentz G, Mormann M, Kucerova D, Muller FU, Schmitz W, Schulze-Bahr E, Wilde AA, Neumann J. The human CASQ2 mutation K206N is associated with hyperglycosylation and altered cellular calcium handling. J Mol Cell Cardiol 49: 95-105, 2010.
47. Knollmann BC. New roles of calsequestrin and triadin in cardiac muscle. J Physiol 587: 3081-3087, 2009.
48. Knollmann BC. Power and pitfalls of using transgenic mice to optimize therapy for CPVT: a need for prospective placebo-controlled clinical trials in genetic arrhythmia disorders. Heart Rhythm 7: 1683-1685, 2010.
49. Knollmann BC. A "rough" journey to the sarcoplasmic reticulum-implications of altered calsequestrin trafficking for cardiac arrhythmia. J Mol Cell Cardiol 49: 554-555, 2010.
50. 2+ release, and catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 116: 2510-2520, 2006.
51. Kornyeyev D, Petrosky AD, Zepeda B, Ferreiro M, Knollmann B, Escobar AL. Calsequestrin 2 deletion shortens the refractoriness of Ca(2+) release and reduces rate-dependent Ca(2+)-alternans in intact mouse hearts. J Mol Cell Cardiol 52: 21-31, 2011.
52. 2+ release in subepicardial myocytes of intact beating mouse hearts: effect of exogenous buffers. Am J Physiol Heart Circ Physiol 298: H2138-H2153, 2010.
53. Lahat H, Eldar M. Autosomal recessive catecholamine-induced polymorphic ventricular tachycardia. Isr Med Assoc J 4: 1095-1096, 2002.
54. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A, Lorber A, Kastner DL, Goldman B, Pras E. Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 103: 2822-2827, 2001.
55. Lahat H, Pras E, Olender T, Avidan N, Ben-Asher E, Man O, Levy-Nissenbaum E, Khoury A, Lorber A, Goldman B, Lancet D, Eldar M. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet 69: 1378-1384, 2001.
56. Leenhardt A, Lucet V, Denjoy I, Grau F, Ngoc DD, Coumel P. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients. Circulation 91: 1512-1519, 1995.
57. 2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. J Clin Invest 118: 2230-2245, 2008.
58. Lehnart SE, Wehrens XH, Laitinen PJ, Reiken SR, Deng SX, Cheng Z, Landry DW, Kontula K, Swan H, Marks AR. Sudden death in familial polymorphic ventricular tachycardia associated with calcium release channel (ryanodine receptor) leak. Circulation 109: 3208-3214, 2004.
59. Liu N, Denegri M, Ruan Y, Avelino-Cruz JE, Perissi A, Negri S, Napolitano C, Coetzee WA, Boyden PA, Priori SG. Short communication: flecainide exerts an antiarrhythmic effect in a mouse model of catecholaminergic polymorphic ventricular tachycardia by increasing the threshold for triggered activity. Circ Res 109: 291-295, 2011.
60. Liu OZ, Lederer WJ, Sobie EA. Does the Goldilocks Principle apply to calcium release restitution in heart cells? J Mol Cell Cardiol, 2011.
61. Liu QQ, Oberti C, Zhang XQ, Ke T, Zhang T, Scheinman M, Hu DY, Wang QK. [A novel mutation of F189L in CASQ2 in families with catecholaminergic polymorphic ventricular tachycardia]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 334-337, 2008.
62. Lukyanenko V, Viatchenko-Karpinski S, Smirnov A, Wiesner TF, Gyorke S. Dynamic regulation of sarcoplasmic reticulum Ca(2+) content and release by luminal Ca(2+)-sensitive leak in rat ventricular myocytes. Biophys J 81: 785-798, 2001.
63. MacLennan DH, Wong PT. Isolation of a calcium-sequestering protein from sarcoplasmic reticulum. Proc Natl Acad Sci USA 68: 1231-1235, 1971.
64. McFarland TP, Milstein ML, Cala SE. Rough endoplasmic reticulum to junctional sarcoplasmic reticulum trafficking of calsequestrin in adult cardiomyocytes. J Mol Cell Cardiol 49: 556-564, 2010.
65. Mohamed U, Gollob MH, Gow RM, Krahn AD. Sudden cardiac death despite an implantable cardioverter-defibrillator in a young female with catecholaminergic ventricular tachycardia. Heart Rhythm 3: 1486-1489, 2006.
66. 2+-binding protein changes in CSQ2 knockout mice. Am J Physiol Heart Circ Physiol 300: H595-H604, 2011.
67. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4: 675-678, 2007.
68. Novak A, Binah O, Itskovitz-Eldor J, Barad L, Zeevi-Levin N. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation. J Cell Mol Med 2011 Nov 2 [Epub ahead of print].
69. Park H, Park IY, Kim E, Youn B, Fields K, Dunker AK, Kang C. Comparing skeletal and cardiac calsequestrin structures and their calcium binding: a proposed mechanism for coupled calcium binding and protein polymerization. J Biol Chem 279: 18026-18033, 2004.
70. 2+ regulation. J Biol Chem 278: 16176-16182, 2003.
71. Pastore JM, Girouard SD, Laurita KR, Akar FG, Rosenbaum DS. Mechanism linking T-wave alternans to the genesis of cardiac fibrillation. Circulation 99: 1385-1394, 1999.
72. Pertille A, de Carvalho CL, Matsumura CY, Neto HS, Marques MJ. Calcium-binding proteins in skeletal muscles of the mdx mice: potential role in the pathogenesis of Duchenne muscular dystrophy. Int J Exp Pathol 91: 63-71, 2010.
73. Pizzale S, Gollob MH, Gow R, Birnie DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 19: 1319-1321, 2008.
74. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodiumcalcium exchange, inward rectifier potassium current, and residual betaadrenergic responsiveness. Circ Res 88: 1159-1167, 2001.
75. Postma AV, Denjoy I, Hoorntje TM, Lupoglazoff JM, Da Costa A, Sebillon P, Mannens MM, Wilde AA, Guicheney P. Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ Res 91: e21-e26, 2002.
76. Postma AV, Denjoy I, Kamblock J, Alders M, Lupoglazoff JM, Vaksmann G, Dubosq-Bidot L, Sebillon P, Mannens MM, Guicheney P, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 42: 863-870, 2005.
77. Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, DeSimone L, Coltorti F, Bloise R, Keegan R, Cruz Filho FE, Vignati G, Benatar A, DeLogu A. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 106: 69-74, 2002.
78. Priori SG, Napolitano C, Tiso N, Memmi M, Vignati G, Bloise R, Sorrentino V, Danieli GA. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 103: 196-200, 2001.
79. 2+ regulation of single cardiac ryanodine receptors: insights provided by calsequestrin and its mutants. J Gen Physiol 131: 325-334, 2008.
80. Rizzi N, Liu N, Napolitano C, Nori A, Turcato F, Colombi B, Bicciato S, Arcelli D, Spedito A, Scelsi M, Villani L, Esposito G, Boncompagni S, Protasi F, Volpe P, Priori SG. Unexpected structural and functional consequences of the R33Q homozygous mutation in cardiac calsequestrin: a complex arrhythmogenic cascade in a knock in mouse model. Circ Res 103: 298-306, 2008.
81. Rosso R, Kalman JM, Rogowski O, Diamant S, Birger A, Biner S, Belhassen B, Viskin S. Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm 4: 1149-1154, 2007.
82. Sato Y, Ferguson DG, Sako H, Dorn GW, Kadambi VJ II, Yatani A, Hoit BD, Walsh RA, Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 273: 28470-28477, 1998.
83. Schwartz PJ, Stramba-Badiale M, Crotti L, Pedrazzini M, Besana A, Bosi G, Gabbarini F, Goulene K, Insolia R, Mannarino S, Mosca F, Nespoli L, Rimini A, Rosati E, Salice P, Spazzolini C. Prevalence of the congenital long-QT syndrome. Circulation 120: 1761-1767, 2009.
84. Scriven DR, Dan P, Moore ED. Distribution of proteins implicated in excitation-contraction coupling in rat ventricular myocytes. Biophys J 79: 2682-2691, 2000.
85. 2+ overload induces arrhythmogenic events in mouse cardiomyocytes with a human CPVT mutation. Cardiovasc Res 87: 50-59, 2010.
86. 2+ leak-load relationship. Circ Res 91: 594-600, 2002.
87. Slupsky JR, Ohnishi M, Carpenter MR, Reithmeier RA. Characterization of cardiac calsequestrin. Biochemistry 26: 6539-6544, 1987.
88. Song L, Alcalai R, Arad M, Wolf CM, Toka O, Conner DA, Berul CI, Eldar M, Seidman CE, Seidman JG. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia. J Clin Invest 117: 1814-1823, 2007.
89. Sonmez O, Gul EE, Duman C, Duzenli MA, Tokac M, Cooper J. Type II bidirectional ventricular tachycardia in a patient with myocardial infarction. J Electrocardiol 42: 631-632, 2009.
90. Spurney CF, Knoblach S, Pistilli EE, Nagaraju K, Martin GR, Hoffman EP. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 18: 371-381, 2008.
91. 2+ in cardiomyocytes. J Physiol 587: 4863-4872, 2009.
92. Swan H, Laitinen P, Kontula K, Toivonen L. Calcium channel antagonism reduces exercise-induced ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia patients with RyR2 mutations. J Cardiovasc Electrophysiol 16: 162-166, 2005.
93. Swan H, Piippo K, Viitasalo M, Heikkila P, Paavonen T, Kainulainen K, Kere J, Keto P, Kontula K, Toivonen L. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts. J Am Coll Cardiol 34: 2035-2042, 1999.
94. Terentyev D, Nori A, Santoro M, Viatchenko-Karpinski S, Kubalova Z, Gyorke I, Terentyeva R, Vedamoorthyrao S, Blom NA, Valle G, Napolitano C, Williams SC, Volpe P, Priori SG, Gyorke S. Abnormal interactions of calsequestrin with the ryanodine receptor calcium release channel complex linked to exercise-induced sudden cardiac death. Circ Res 98: 1151-1158, 2006.
95. Terentyev D, Viatchenko-Karpinski S, Vedamoorthyrao S, Oduru S, Gyorke I, Williams SC, Gyorke S. Protein protein interactions between triadin and calsequestrin are involved in modulation of sarcoplasmic reticulum calcium release in cardiac myocytes. J Physiol 583: 71-80, 2007.
96. Townsend D, Yasuda S, McNally E, Metzger JM. Distinct pathophysiological mechanisms of cardiomyopathy in hearts lacking dystrophin or the sarcoglycan complex. FASEB J 25: 3106-3114, 2011.
97. van der Werf C, Kannankeril PJ, Sacher F, Krahn AD, Viskin S, Leenhardt A, Shimizu W, Sumitomo N, Fish FA, Bhuiyan ZA, Willems AR, van der Veen MJ, Watanabe H, Laborderie J, Haissaguerre M, Knollmann BC, Wilde AA. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol 57: 2244-2254, 2011.
98. Vassalle M, Lin CI. Calcium overload and cardiac function. J Biomed Sci 11: 542-565, 2004.
99. Verrier RL, Klingenheben T, Malik M, El-Sherif N, Exner DV, Hohnloser SH, Ikeda T, Martinez JP, Narayan SM, Nieminen T, Rosenbaum DS. Microvolt T-wave alternans physiological basis, methods of measurement, and clinical utility- consensus guideline by International Society for Holter and Noninvasive Electrocardiology. J Am Coll Cardiol 58: 1309-1324, 2011.
100. Wang S, Trumble WR, Liao H, Wesson CR, Dunker AK, Kang CH. Crystal structure of calsequestrin from rabbit skeletal muscle sarcoplasmic reticulum. Nat Struct Biol 5: 476-483, 1998.
101. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE, Duff HJ, Roden DM, Wilde AA, Knollmann BC. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15: 380-383, 2009.
102. Wehrens XH, Lehnart SE, Reiken S, Vest JA, Wronska A, Marks AR. Ryanodine receptor/calcium release channel PKA phosphorylation: a critical mediator of heart failure progression. Proc Natl Acad Sci USA 103: 511-518, 2006.
103. 2 handling in very-long-chain acyl-CoA dehydrogenase null mice. Am J Physiol Heart Circ Physiol 292: H2202-H2211, 2007.
104. Wilson LD, Rosenbaum DS. Mechanisms of arrythmogenic cardiac alternans. Europace 9, Suppl 6: vi77-82, 2007.
105. Wong CH, Koo SH, She GQ, Chui P, Lee EJ. Genetic variability of RyR2 and CASQ2 genes in an Asian population. Forensic Sci Int 192: 53-55, 2009.
106. Yu L, Shi E, Gu T. Single-stage repair of interrupted aortic arch with simultaneous coronary artery bypass grafting without cardiopulmonary bypass in an adult. Ann Thorac Surg 92: 1110-1113, 2011.
107. Yuan Q, Fan GC, Dong M, Altschafl B, Diwan A, Ren X, Hahn HH, Zhao W, Waggoner JR, Jones LR, Jones WK, Bers DM, Dorn GW, Wang HS II, Valdivia HH, Chu G, Kranias EG. Sarcoplasmic reticulum calcium overloading in junctin deficiency enhances cardiac contractility but increases ventricular automaticity. Circulation 115: 300-309, 2007.
108. Zhang L, Kelley J, Schmeisser G, Kobayashi YM, Jones LR. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. J Biol Chem 272: 23389-23397, 1997.
109. Zhou Q, Xiao J, Jiang D, Wang R, Vembaiyan K, Wang A, Smith CD, Xie C, Chen W, Zhang J, Tian X, Jones PP, Zhong X, Guo A, Chen H, Zhang L, Zhu W, Yang D, Li X, Chen J, Gillis AM, Duff HJ, Cheng H, Feldman AM, Song LS, Fill M, Back TG, Chen SR. Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca(2+) release. Nat Med 17: 1003-1009, 2011.
110. Zima AV, Qin J, Fill M, Blatter LA. Tricyclic antidepressant amitriptyline alters sarcoplasmic reticulum calcium handling in ventricular myocytes. Am J Physiol Heart Circ Physiol 295: H2008-H2016, 2008.